Recent Progress in Human Milk Oligosaccharides and Its Antiviral Efficacy

Gastrointestinal (GI)-associated viruses, including rotavirus (RV), norovirus (NV), and enterovirus, usually invade host cells, transmit, and mutate their genetic information, resulting in influenza-like symptoms, acute gastroenteritis, encephalitis, or even death. The unique structures of human mil...

Full description

Saved in:
Bibliographic Details
Published in:Journal of agricultural and food chemistry 2024-04, Vol.72 (14), p.7607-7617
Main Authors: Chen, Yihan, Chen, Zhengxin, Zhu, Yingying, Wen, Yuxi, Zhao, Chao, Mu, Wanmeng
Format: Article
Language:English
Subjects:
Antiviral Agents - pharmacology
Child
Humans
Immune System
Infant
Milk, Human - chemistry
Oligosaccharides - metabolism
Rotavirus - genetics
Rotavirus - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal (GI)-associated viruses, including rotavirus (RV), norovirus (NV), and enterovirus, usually invade host cells, transmit, and mutate their genetic information, resulting in influenza-like symptoms, acute gastroenteritis, encephalitis, or even death. The unique structures of human milk oligosaccharides (HMOs) enable them to shape the gut microbial diversity and endogenous immune system of human infants. Growing evidence suggests that HMOs can enhance host resistance to GI-associated viruses but without a systematic summary to review the mechanism. The present review examines the lactose- and neutral-core HMOs and their antiviral effects in the host. The potential negative impacts of enterovirus 71 (EV-A71) and other GI viruses on children are extensive and include neurological sequelae, neurodevelopmental retardation, and cognitive decline. However, the differences in the binding affinity of HMOs for GI viruses are vast. Hence, elucidating the mechanisms and positive effects of HMOs against different viruses may facilitate the development of novel HMO derived oligosaccharides.
ISSN:0021-8561
1520-5118
DOI:10.1021/acs.jafc.3c09460